Delivery Order SPE2DB24D8003-SPE2DB25FJUCD
Award Date
3/28/25
Potential Completion Date
3/31/25
Potential Value
$1.9K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, involves the delivery of Dupixent 300 mg/2 ml syringes to the Defense Logistics Agency (DLA) Troop Support Medical division. The contract has a firm fixed price of $2,345.09 and a period of performance through November 15, 2023. This award is part of Dakota Drug's larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows the company...
This federal contract award, identified as SPE2DB24D8002 and SPE2DB24FJMVF, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc. The contract, valued at $5,405.43, is a firm fixed-price delivery order for the provision of Dupixent 300 mg/2 ml syringes. Dakota Drug, Inc. is a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. As a prime contractor to the DLA Troop Support Medical, the company plays a crucial role...
This federal contract award, with an ID of SPE2DB24D8003|SPE2DB25FJTKZ, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The award is for the delivery of Dupixent 300 mg/2 ml syringes, with a ceiling value of $3,650.51 and a period of performance through December 11, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc. with the DLA, identified as SPE2DB24D8001, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract has a firm fixed price of $3,179.33 and a period of performance through February 26, 2025. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, under the DLA Troop Support Medical's ECAT Generation V Program. This IDC allows...
This federal contract award, valued at $8,116.86, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is a firm fixed-price delivery order for the provision of the pharmaceutical product Dupixent 300 mg/2 ml syringe, 2 ml. This award is associated with a larger Indefinite Delivery Contract (IDC) between Dakota Drug, Inc. and the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,867.25 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product. The award is not associated with a set-aside program. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop Support Medical's ECAT...
This federal contract award, identified as SPE2DB24D8002|SPE2DB25FJNKP, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of Dupixent 300 mg/2 ml syringes, with a ceiling value of $9,629.49 and a period of performance extending through March 31, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense,...
The U.S. government's Defense Logistics Agency (DLA) awarded a $26,588.72 firm-fixed-price delivery order contract (SPE2DX15D8003|SPE2DX24F7D7B) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml syringes. The contract has a performance period through May 8, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (SPE2DB24D8001) as part of the DLA's ECAT...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml pens. The contract, identified as SPE2DB24D8001|SPE2DB25FKZCU, has a ceiling value of $6,688.11 and a period of performance through January 30, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00, which is part of the DLA Troop Support Medical's ECAT...